Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$6.76 -1.6%	$6.22	$3.56 ▼ $12.92	$387.71M	0.48	223,898 shs	414,105 shs
ESPR Esperion Therapeutics	$2.07 +6.7%	$1.31	$0.69 ▼ $3.94	$384.51M	0.82	6.42 million shs	6.61 million shs
NBTX Nanobiotix	$8.20 +4.5%	$5.63	$2.76 ▼ $8.47	$376.35M	0.45	9,959 shs	8,994 shs
TCRX TScan Therapeutics	$1.81 +2.3%	$1.67	$1.02 ▼ $6.23	$100.17M	0.99	265,487 shs	400,820 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	-1.60%	+1.35%	+7.13%	+70.71%	-32.26%
ESPR Esperion Therapeutics	+6.70%	+14.36%	+83.19%	+158.17%	+11.29%
NBTX Nanobiotix	+2.96%	+14.05%	+55.16%	+111.07%	+70.48%
TCRX TScan Therapeutics	+2.26%	+9.70%	+2.26%	+45.97%	-67.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.6866 of 5 stars	3.6	3.0	0.0	3.3	1.7	0.0
ESPR Esperion Therapeutics	3.9772 of 5 stars	3.4	1.0	3.9	3.4	1.7	0.6
NBTX Nanobiotix	0.6744 of 5 stars	1.3	3.0	0.0	2.5	0.0	0.6
TCRX TScan Therapeutics	3.6703 of 5 stars	3.5	5.0	0.0	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.14	Buy	$29.00	328.99% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	238.16% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	-2.44% Downside
TCRX TScan Therapeutics	3.00	Buy	$7.80	330.94% Upside

Current Analyst Ratings Breakdown

Latest TCRX, ESPR, ATXS, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ATXS Astria Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ATXS Astria Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $26.00
8/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/12/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$2.93 per share	N/A
ESPR Esperion Therapeutics	$332.31M	1.23	$0.03 per share	80.75	($1.97) per share	-1.05
NBTX Nanobiotix	$39.18M	10.03	N/A	N/A	($1.51) per share	-5.43
TCRX TScan Therapeutics	$2.82M	36.32	N/A	N/A	$3.12 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$1.87	N/A	N/A	N/A	N/A	-56.39%	-36.08%	N/A
ESPR Esperion Therapeutics	-$51.74M	-$0.49	N/A	N/A	N/A	-35.84%	-0.91%	-28.84%	N/A
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-1,964.88%	-63.33%	-40.19%	N/A

Latest TCRX, ESPR, ATXS, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	-$0.57	+$0.04	-$0.57	$16.00 million	N/A
8/12/2025	Q2 2025	TCRX TScan Therapeutics	-$0.28	-$0.2848	-$0.0048	-$0.28	$1.31 million	$3.08 million
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	-$0.02	+$0.15	-$0.02	$62.55 million	$82.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	14.89	17.39
ESPR Esperion Therapeutics	N/A	1.18	0.81
NBTX Nanobiotix	N/A	1.04	1.04
TCRX TScan Therapeutics	0.18	7.06	8.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
ESPR Esperion Therapeutics	47.39%
NBTX Nanobiotix	38.81%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
ESPR Esperion Therapeutics	1.70%
NBTX Nanobiotix	3.45%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.44 million	53.89 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
NBTX Nanobiotix	100	47.94 million	46.29 million	Not Optionable
TCRX TScan Therapeutics	100	56.59 million	54.13 million	Not Optionable

TCRX, ESPR, ATXS, and NBTX Headlines

Recent News About These Companies

Wedbush Reaffirms Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

August 14 at 2:15 AM | americanbankingnews.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

August 13 at 1:41 PM | marketbeat.com

TScan Therapeutics Reports Q2 2025 Financial Results

August 13 at 8:28 AM | msn.com

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

August 12 at 5:26 PM | msn.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

August 12 at 4:01 PM | zacks.com

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12 at 7:00 AM | globenewswire.com

TScan Therapeutics (TCRX) to Release Quarterly Earnings on Monday

August 10, 2025 | americanbankingnews.com

Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) Price Target at $7.80

August 6, 2025 | americanbankingnews.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

August 5, 2025 | marketbeat.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by Brokerages

August 3, 2025 | marketbeat.com

TScan Therapeutics Elects New Directors at Annual Meeting

July 27, 2025 | theglobeandmail.com

One TScan Therapeutics Insider Raised Stake By 18% In Previous Year

July 19, 2025 | finance.yahoo.com

Tscan Therapeutics Inc News (TCRX) - Investing.com

July 9, 2025 | investing.com

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

What Analysts Are Saying About TScan Therapeutics Stock

May 9, 2025 | nasdaq.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, ESPR, ATXS, and NBTX Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$6.76 -0.11 (-1.60%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.76 +0.00 (+0.07%)

As of 08/14/2025 04:20 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Esperion Therapeutics NASDAQ:ESPR

$2.07 +0.13 (+6.70%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.13 +0.06 (+2.90%)

As of 04:37 AM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Nanobiotix NASDAQ:NBTX

$8.09 +0.24 (+2.99%)

As of 08/14/2025 04:00 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

TScan Therapeutics NASDAQ:TCRX

$1.81 +0.04 (+2.26%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.00 +0.19 (+10.22%)

As of 04:07 AM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time